PT - JOURNAL ARTICLE AU - TAKAFUMI YAMAMOTO AU - NORIHIRO IMAI AU - KENTA YAMAMOTO AU - TAKANORI ITO AU - YOJI ISHIZU AU - TAKASHI HONDA AU - SHUICHI OKAMOTO AU - TAKESHI KANEMATSU AU - NOBUAKI SUZUKI AU - TADASHI MATSUSHITA AU - MASATOSHI ISHIGAMI AU - MITSUHIRO FUJISHIRO TI - Tolerability of Molecular-targeted Agents for Hepatocellular Carcinoma Treatment in Haemophiliacs AID - 10.21873/anticanres.15035 DP - 2021 May 01 TA - Anticancer Research PG - 2569--2573 VI - 41 IP - 5 4099 - http://ar.iiarjournals.org/content/41/5/2569.short 4100 - http://ar.iiarjournals.org/content/41/5/2569.full SO - Anticancer Res2021 May 01; 41 AB - Background: Hepatocellular carcinoma (HCC) is considered a leading cause of death in patients with haemophilia. Recent advances in the treatment of unresectable HCC with molecular-targeted agents (MTAs) have led to better clinical outcomes. However, the tolerability of MTAs by haemophilic patients with HCC remains unclear. Aim: This study aimed to compare the tolerability of MTAs in such patients. Patients and Methods: From January 2011 to October 2020, five haemophilic patients with HCC were treated with MTAs. Adverse events were assessed in comparison with 265 non-haemophilic patients with HCC. Results: The prevalence of hand–foot skin reaction was not higher in the haemophiliacs than in the non-haemophiliacs, whereas the rate of haemorrhagic events was higher in the haemophiliacs (6.0% versus 40.0%, p=0.037). Conclusion: Haemophiliacs tolerate long-term MTA use, without the occurrence of life-threatening complications. However, careful observation and prevention are needed for MTA-related gastrointestinal bleeding in haemophiliacs.